Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inspire Medical Systems (INSP) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Inspire Medical Systems (INSP) over the last 9 years, with Q4 2025 value amounting to -$48.3 million.

  • Inspire Medical Systems' Cash from Financing Activities rose 3112.44% to -$48.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$183.4 million, marking a year-over-year decrease of 25014.03%. This contributed to the annual value of -$183.4 million for FY2025, which is 25014.03% down from last year.
  • Inspire Medical Systems' Cash from Financing Activities amounted to -$48.3 million in Q4 2025, which was up 3112.44% from -$51.1 million recorded in Q3 2025.
  • Over the past 5 years, Inspire Medical Systems' Cash from Financing Activities peaked at $224.1 million during Q3 2022, and registered a low of -$87.8 million during Q1 2025.
  • Its 5-year average for Cash from Financing Activities is $1.4 million, with a median of $3.5 million in 2021.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 573203.23% in 2022, then tumbled by 1152708.33% in 2025.
  • Inspire Medical Systems' Cash from Financing Activities (Quarter) stood at $4.1 million in 2021, then surged by 78.83% to $7.3 million in 2022, then crashed by 238.77% to -$10.1 million in 2023, then plummeted by 593.41% to -$70.1 million in 2024, then skyrocketed by 31.12% to -$48.3 million in 2025.
  • Its last three reported values are -$48.3 million in Q4 2025, -$51.1 million for Q3 2025, and $3.7 million during Q2 2025.